SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-383502"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-383502" > Rhabdomyosarcoma di...

  • Sparber-Sauer, MonikaKlinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany (författare)

Rhabdomyosarcoma diagnosed in the first year of life : Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-02-14
  • Wiley,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-383502
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-383502URI
  • https://doi.org/10.1002/pbc.27652DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background Rhabdomyosarcoma (RMS) diagnosed during the first year of life is reported to have poor outcome. Little is known about treatment and outcome data of relapsed disease (RD).MethodsCharacteristics, treatment, and outcome of 155 patients <= 12 months registered within the Cooperative Weichteilsarkom Studiengruppe (CWS) between 1981 and 2016 were evaluated.Results Localized disease (LD) was diagnosed in 144 patients and metastatic disease (MD) in 11. The histological diagnosis was alveolar (RMA) (n = 38, 23/25 examined patients PAX7/3:FOXO1-positive), embryonal (RME) (n = 100), botryoid (n = 10), anaplastic (n = 1), and spindle-cell RMS (n = 6). Multimodal treatment including conventional (age-adjusted) chemotherapy (CHT) (n = 150), resection (n = 137), and radiotherapy (RT) (n = 37) was administered. Complete remission was achieved in 129 of 144 patients with LD. RD occurred in 51 infants at a median age of 1.7 years (range, 0.3-8.8). Sixty-three percent of patients with RMA suffered RD, in contrast to 28% of patients with RME. Relapse treatment consisted of conventional CHT (n = 48), resection (n = 28), and RT (n = 21). The pattern of relapse and best resection were significant prognostic factors for patients with RD (P = 0.000 and P = 0.002). Late effects occurred as secondary malignancies in 6%, long-term toxicity in 21%, and resection-related impairment in 33% of the 105 surviving patients. The 5-year event-free survival and overall survival for infants with initial LD were 51% and 69%, 14% and 14% for patients with initial MD and 39% and 41% for relapsed patients, respectively.Conclusion Multimodal treatment including microscopically complete resection is strongly recommended to achieve a good prognosis in LD and RD of infants with RMS.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Stegrnaier, SabineKlinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany (författare)
  • Vokuhl, ChristianKiel Pediat Tumor Registry, Dept Pathol, Sect Pediat Pathol, Kiel, Germany (författare)
  • Seitz, GuidoUniv Childrens Hosp Marburg, Dept Pediat Surg, Marburg, Germany (författare)
  • von Kalle, TheklaOlga Hosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Klinikum Stuttgart,Inst Radiol, Stuttgart, Germany (författare)
  • Scheer, MonikaKlinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany (författare)
  • Muenter, MarcKlinikum Stuttgart, Inst Radiotherapy, Stuttgart, Germany (författare)
  • Bielack, Stefan S.Klinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany;Univ Munster, Dept Pediat Hematol & Oncol, Munster, Germany (författare)
  • Weclawek-Tompol, JadwigaUniv Wroclaw, Dept Pediat Hematol Oncol & BMT, Wroclaw, Poland (författare)
  • Ladenstein, RuthSt Anna Childrens Hosp, Pediat Oncol, Vienna, Austria (författare)
  • Niggli, FelixUniv Zurich, Dept Pediat Oncol, Zurich, Switzerland (författare)
  • Ljungman, Gustaf,1958-Uppsala universitet,Barnneurologi/Barnonkologi(Swepub:uu)gustaflm (författare)
  • Fuchs, JoergUniv Childrens Hosp, Dept Pediat Surg & Urol, Tubingen, Germany (författare)
  • Hettmer, SimoneUniv Freiburg, Fac Med, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Freiburg, Germany (författare)
  • Koscielniak, EwaKlinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany;Childrens Hosp, Dept Pediat Hematol & Oncol, Tubingen, Germany (författare)
  • Klingebiel, ThomasUniv Hosp Frankfurt, Dept Children & Adolescents, Frankfurt, Germany (författare)
  • Klinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Zentrum Kinder Jugend & Frauenmed, Pediat Oncol Hematol Immunol 5, Stuttgart, GermanyKiel Pediat Tumor Registry, Dept Pathol, Sect Pediat Pathol, Kiel, Germany (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Pediatric Blood & Cancer: Wiley66:61545-50091545-5017

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy